Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: The ACCORD trial

Clinical Journal of the American Society of Nephrology

Volumn 11, Issue 8, 2016, Pages 1343-1352

  Nadkarni, Girish N ^a   Rao, Veena ^b   Ismail Beigi, Faramarz ^c   Fonseca, Vivian A ^d   Shah, Sudhir V ^e   Simonson, Michael S ^c   Cantley, Lloyd ^b   Devarajan, Prasad ^f   Parikh, Chirag R ^b   Coca, Steven G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f UNIVERSITY OF CINCINNATI   (United States)

Author keywords

albuminuria; Biomarkers; CCL2 protein, human; CHI3L1 protein, human; chronic kidney disease; Diabetes Mellitus, Type 2; Follow Up Studies; Inflammation; renal fibrosis; renal injury

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE; FENOFIBRATE; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 18 BINDING PROTEIN; KIDNEY INJURY MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; SERUM ALBUMIN; SIMVASTATIN; SULFONYLUREA; BIOLOGICAL MARKER; CCL2 PROTEIN, HUMAN; CHI3L1 PROTEIN, HUMAN; CHITINASE 3 LIKE PROTEIN 1; CREATININE; HAVCR1 PROTEIN, HUMAN; INTERLEUKIN 18; INTERLEUKIN 18 PROTEIN, HUMAN;

ADULT; AGED; ALBUMINURIA; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFLAMMATION; KIDNEY FIBROSIS; KIDNEY FUNCTION TEST; KIDNEY INJURY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; RECEPTOR UPREGULATION; RISK FACTOR; SPECTROMETRY; DIABETIC NEPHROPATHY; FIBROSIS; GLOMERULUS FILTRATION RATE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); URINE;

AGED; BIOMARKERS; CASE-CONTROL STUDIES; CHEMOKINE CCL2; CHITINASE-3-LIKE PROTEIN 1; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; FIBROSIS; GLOMERULAR FILTRATION RATE; HEPATITIS A VIRUS CELLULAR RECEPTOR 1; HUMANS; INFLAMMATION; INTERLEUKIN-18; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85013363342     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.12051115     Document Type: Article

References (41)

1. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J: Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 305: 2532-2539, 2011
2. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang Y-H, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose): National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 378: 31-40, 2011
3. Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, de Boer IH: Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 24: 302-308, 2013
4. Dunkler D, Gao P, Lee SF, Heinze G, Clase CM, Tobe S, Teo KK, Gerstein H, Mann JF, Oberbauer R, ONTARGET and ORIGIN Investigators: Risk prediction for early CKD in type 2 diabetes. Clin J Am Soc Nephrol 10: 1371-1379, 2015
5. Araki S, Haneda M, Sugimoto T, Isono M, Isshiki K, Kashiwagi A, Koya D: Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 54: 2983-2987, 2005
6. Nosadini R, Velussi M, Brocco E, Bruseghin M, Abaterusso C, Saller A, Dalla Vestra M, Carraro A, Bortoloso E, Sambataro M, Barzon I, Frigato F, Muollo B, Chiesura-Corona M, Pacini G, Baggio B, Piarulli F, Sfriso A, Fioretto P: Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. Diabetes 49: 476-484, 2000
7. Gerstein HC, Miller ME, Byington RP, Goff DC Jr., Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr., Probstfield JL, Simons-Morton DG, Friedewald WT; Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545-2559, 2008
8. Titan SM, Vieira JM., Jr., Dominguez WV, Moreira SRS, Pereira AB, Barros RT, Zatz R: Urinary MCP-1 and RBP: Independent predictors of renal outcome in macroalbuminuric diabetic nephropathy. J Diabetes Complications 26: 546-553, 2012
9. Verhave JC, Bouchard J, Goupil R, Pichette V, Brachemi S, Madore F, Troyanov S: Clinical value of inflammatory urinary biomarkers in overt diabetic nephropathy: A prospective study. Diabetes Res Clin Pract 101: 333-340, 2013
10. Shlipak MG, Scherzer R, Abraham A, Tien PC, Grunfeld C, Peralta CA, Devarajan P, Bennett M, Butch AW, Anastos K, Cohen MH, Nowicki M, Sharma A, Young MA, Sarnak MJ, Parikh CR: Urinary markers of kidney injury and kidney function decline in HIV-infected women. J Acquir Immune Defic Syndr 61: 565-573, 2012
11. Peralta CA, Katz R, Bonventre JV, Sabbisetti V, Siscovick D, Sarnak M, Shlipak MG: Associations of urinary levels of kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) with kidney function decline in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 60: 904-911, 2012
12. Żurawska-Płaksej E, Ługowska A, Hetmańczyk K, Knapik-Kordecka M, Adamiec R, Piwowar A: Proteins from the 18 glycosyl hydrolase family are associated with kidney dysfunction in patients with diabetes type 2. Biomarkers 20: 52-57, 2015
13. Hall IE, Stern EP, Cantley LG, Elias JA, Parikh CR: Urine YKL-40 is associated with progressive acute kidney injury or death in hospitalized patients. BMC Nephrol 15: 133, 2014
14. Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, Arima H, Chadban SJ, Cirillo M, Djurdjev O, Green JA, Heine GH, Inker LA, Irie F, Ishani A, Ix JH, Kovesdy CP, Marks A, Ohkubo T, Shalev V, Shankar A, Wen CP, de Jong PE, Iseki K, Stengel B, Gansevoort RT, Levey AS; CKD Prognosis Consortium: Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 311: 2518-2531, 2014
15. O’Seaghdha CM, Hwang S-J, Larson MG, Meigs JB, Vasan RS, Fox CS: Analysis of a urinary biomarker panel for incident kidney disease and clinical outcomes. J Am Soc Nephrol 24: 1880-1888, 2013
16. Mychaleckyj JC, Craven T, Nayak U, Buse J, Crouse JR, Elam M, Kirchner K, Lorber D, Marcovina S, Sivitz W, Sperl-Hillen J, Bonds DE, Ginsberg HN: Reversibility of fenofibrate therapyinduced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care 35: 1008-1014, 2012
17. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009
18. Stevens LA, Schmid CH, Greene T, Zhang YL, Beck GJ, Froissart M, Hamm LL, Lewis JB, Mauer M, Navis GJ, Steffes MW, Eggers PW, Coresh J, Levey AS: Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis 56: 486-495, 2010
19. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G; National Kidney Foundation: National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 139: 137-147, 2003
20. Ferenbach D, Kluth DC, Hughes J: Inflammatory cells in renal injury and repair. Semin Nephrol 27: 250-259, 2007
21. Kanasaki K, Taduri G, Koya D: Diabetic nephropathy: The role of inflammation in fibroblast activation and kidney fibrosis. Front Endocrinol (Lausanne) 4: 7, 2013
22. Tesch GH: MCP-1/CCL2: A new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 294: F697-F701, 2008
23. Rovin BH, Rumancik M, Tan L, Dickerson J: Glomerular expression of monocyte chemoattractant protein-1 in experimental and human glomerulonephritis. Lab Invest 71: 536-542, 1994
24. Ihm CG, Park JK, Hong SP, Lee TW, Cho BS, Kim MJ, Cha DR, Ha H: A high glucose concentration stimulates the expression of monocyte chemotactic peptide 1 in human mesangial cells. Nephron 79: 33-37, 1998
25. Banba N, Nakamura T, Matsumura M, Kuroda H, Hattori Y, Kasai K: Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 58: 684-690, 2000
26. Matsui T, Yamagishi S, Ueda S, Nakamura K, Imaizumi T, Takeuchi M, Inoue H: Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation. J IntMed Res 35: 482-489, 2007
27. Kanamori H, Matsubara T, Mima A, Sumi E, Nagai K, Takahashi T, Abe H, Iehara N, Fukatsu A, Okamoto H, Kita T, Doi T, Arai H: Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun 360: 772-777, 2007
28. Camilla R, Brachemi S, Pichette V, Cartier P, Laforest-Renald A, MacRae T, Madore F, Troyanov S: Urinary monocyte chemotactic protein 1: Marker of renal function decline in diabetic and nondiabetic proteinuric renal disease. J Nephrol 24: 60-67, 2011
29. Bragt MCE, Plat J, Mensink M, Schrauwen P, Mensink RP: Anti-inflammatory effect of rosiglitazone is not reflected in expression of NFkappaB-related genes in peripheral blood mononuclear cells of patients with type 2 diabetes mellitus. BMC Endocr Disord 9: 8, 2009
30. Faubel S, Edelstein CL: Caspases as drug targets in ischemic organ injury. Curr Drug Targets Immune Endocr Metabol Disord 5: 269-287, 2005
31. Parikh CR, Jani A, Melnikov VY, Faubel S, Edelstein CL: Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis 43: 405-414, 2004
32. Siew ED, Ikizler TA, Gebretsadik T, Shintani A, Wickersham N, Bossert F, Peterson JF, Parikh CR, May AK, Ware LB: Elevated urinary IL-18 levels at the time of ICU admission predict adverse clinical outcomes. Clin J Am Soc Nephrol 5: 1497-1505, 2010
33. Miyauchi K, Takiyama Y, Honjyo J, Tateno M, Haneda M: Upregulated IL-18 expression in type 2 diabetic subjects with nephropathy: TGF-beta1 enhanced IL-18 expression in human renal proximal tubular epithelial cells. Diabetes Res Clin Pract 83: 190-199, 2009
34. Bonventre JV, Yang L: Kidney injury molecule-1. Curr Opin Crit Care 16: 556-561, 2010
35. Parikh CR, Thiessen-Philbrook H, Garg AX, Kadiyala D, Shlipak MG, Koyner JL, Edelstein CL, Devarajan P, Patel UD, Zappitelli M, Krawczeski CD, Passik CS, Coca SG; TRIBE-AKI Consortium: Performance of kidney injury molecule-1 and liver fatty acidbinding protein and combined biomarkers of AKI after cardiac surgery. Clin J Am Soc Nephrol 8: 1079-1088, 2013
36. Liangos O, Perianayagam MC, Vaidya VS, Han WK, Wald R, Tighiouart H, MacKinnon RW, Li L, Balakrishnan VS, Pereira BJG, Bonventre JV, Jaber BL: Urinary N-acetyl-b-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol 18: 904-912, 2007
37. Fufaa GD, Weil EJ, Nelson RG, Hanson RL, Bonventre JV, Sabbisetti V, Waikar SS, Mifflin TE, Zhang X, Xie D, Hsu C-Y, Feldman HI, Coresh J, Vasan RS, Kimmel PL, Liu KD; Chronic Kidney Disease Biomarkers Consortium Investigators: Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus. Diabetologia 58: 188-198, 2015
38. Bhavsar NA, Köttgen A, Coresh J, Astor BC: Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM-1) as predictors of incident CKD stage 3: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 60: 233-240, 2012
39. Schmidt IM, Hall IE, Kale S, Lee S, He C-H, Lee Y, Chupp GL, Moeckel GW, Lee CG, Elias JA, Parikh CR, Cantley LG: Chitinase-like protein Brp-39/YKL-40 modulates the renal response to ischemic injury and predicts delayed allograft function. J Am Soc Nephrol 24: 309-319, 2013
40. Pena MJ, Heinzel A, Heinze G, Alkhalaf A, Bakker SJL, Nguyen TQ, Goldschmeding R, Bilo HJG, Perco P, Mayer B, de Zeeuw D, LambersHeerspink HJ: A panel of novel biomarkers representing different disease pathways improves prediction of renal function decline in type 2 diabetes. PLoS One 10: e0120995, 2015
41. Nielsen SE, Rossing K, Hess G, Zdunek D, Jensen BR, Parving H-H, Rossing P: The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP. Scand J Clin Lab Invest 72: 137-142, 2012